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EDITORIAL
‘There should be no financial disincentives to living donors.
All donors should be legally entitled to reimbursement of those
expenses incurred solely by the act of donation. Appropriate
compensation for pain, discomfort and inconvenience suffered
by living donors, is morally acceptable and may be adopted in
a regulated fashion. The well established position of
transplantation societies against commerce in organs has not
been effective in stopping the rapid growth of such transplants
around the world.  Individual countries will need to study
alternative, locally relevant models, considered ethical in their
societies, which would increase the number of transplants,
protect and respect the donor, and reduce the likelihood of
rampant, unregulated commerce.’1
The mantra that commerce in organ donation is unacceptable
is being challenged. Ethical dilemmas involving the allocation
of scarce donor organs remain controversial.2 Owing to the
critical international shortage of cadaveric donors, boundaries
are being pushed to meet the needs of potential recipients.
Constant reappraisal of these ethical and moral issues is
therefore appropriate. Issues that relate to cultural and
economic imperialism and pronouncements of transplant
societies may also require re-evaluation.  A Human Tissue Act
or its equivalent usually governs legislation on the donation of
human tissue in various countries and is in line with the
mission of internationally recognised organ transplant
societies. In general, such acts are congruous with the South
African Human Tissue Act3 which states that ‘It is an offence to
charge a fee in relation to the donation of human organs’.  In
many countries the lay press reports that ‘the sale of body parts
is now coming of age’.4 Terms such as ‘rewarded gifting’ and
‘donor’ are changing to terms such as ‘vendor’, opening a
Pandora’s box.5
Cameron and Hoffenberg6 feel strongly that arguments in
favour of the sale of organs are sufficiently cogent to warrant
further discussion. An overview of arguments for and against
commercialisation is as follows:
1. Against commercialisation: organs are priceless and
donated for altruistic reasons. They are seen as a gift, freely
given, never bought or sold. 
For commercialisation: deontological experience indicates
that the supply of blood is only maintained by offering money,
and that altruism has failed to supply organs to meet demand.
2. Against commercialisation: paid organ donation inhibits
cadaver donation and the development of cadaver
programmes.
For commercialisation: live donation is only a supplement to
cadaver donation; payment will be demanded by relatives of
cadaver donors, and payment to live donors is compensation
for pain, discomfort, inconvenience and the risk of operation.
3. Against commercialisation: paid donation exploits the
donor and diminishes autonomy. Paid donors in developing
countries are poor and ignorant concerning organ donation, are
exploited, and lose autonomy. The concept of a ‘reward gift’ is
a cosmetic exercise concealing the true commercial reality. 
For commercialisation: prohibition removes the best or only
option the donor may have of earning money for an important
cause, thus depriving the individual of autonomy.
4. Against commercialisation: paid living transplantation is
performed in poor circumstances and increases risks to the
donor. Conditions are medically far from ideal and success
rates are low, commercial objectives encourage poor pre- and
aftercare of donors, and inadequate screening for disease
increases the risk to donor and recipient.
For commercialisation: actual risk of loss of life during
kidney donation is estimated to be ~ 0.03%, and the
marginalisation of paid living donation leads to its
performance in less than ideal circumstances.
5. Against commercialisation: purchase of organs allows
rich individuals to ‘jump the queue’, which is inequitable.
Access is denied to poor recipients because of lack of money,
thus denying the basic ethical principle of justice. 
For commercialisation: all organs would be sold to a central,
properly controlled agency to minimise exploitation, thereby
ensuring informed consent from the donor. Adequate pre-
donor screening would be performed, and the agency would
ensure that the organs are properly stored and matched with
potential recipients and allocated according to medical or social
need, not to the highest bidder.
Equally disturbing is the use of executed prisoners as organ
donors. In the developing world there are additional socio-
economic, indigenous and cultural, religious and ethical issues
to consider. In addition, strategies to expand the pool of living
donors that are ethically sound and morally acceptable must
keep pace with recent advances in medicine. 
The Iranian live unrelated transplantation model is
financially driven and is being studied by many countries with
great interest. Following the Islamic Revolution in Iran in 1979
renal transplantation was discontinued, the haemodialysis
programme was in jeopardy and group patient deaths
occurred.  For religious reasons, cadaveric organs are not
available.  After an initial limited live related donor
transplantation programme, the government sponsored a
financial compensation model for living donors in 1996.7
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Currently 1 200 renal transplantations are performed annually
through this model. At present Iran has no renal
transplantation waiting list.
It is the contention of the ethicist that ‘As long as
transplantation provides the only hope for the remedy of fatal
conditions, and the demand outstrips supply, the issue of organ
selling will not go away. As long as organ sales are illegal, there
will be a black market.  Legalisation provides the only hope for
control and the protection for both sellers and buyers.’8
Clearly the ethical dilemmas arising from the contentious
issue of commercialisation of organs for transplantation require
serious interdisciplinary debate among medical professionals,
ethicists, lawyers, politicians, theologians, religious leaders and
the public.  These views should contribute to policy
formulation and relevant evolving legislature.  
K S Satyapal
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